Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

HUMULIN I KwikPen (Isophane) 100IU/ml suspension for injection

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Human insulin may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

What it is and what it is used for

for

Humulin I KwikPen is a pre-filled pen containing the active substance human insulin, which is used to treat diabetes. You get diabetes if your pancreas does not make enough insulin to control the level of glucose in your blood (blood sugar). Humulin I is used to control glucose in the long term. Its action is prolonged by the inclusion of protamine sulfate in the suspension. Your doctor may tell you to use Humulin I KwikPen as well as a fast-acting insulin. Each kind of insulin comes with its own patient information leaflet to tell you about it. Do not change your insulin unless your doctor tells you to. Be very careful if you do change insulin. Each type of insulin has a different colour and symbol on the pack and the pen so that you can easily tell the difference. 2.

What you need to know before you take it

e Humulin I KwikPen

Humulin I in pre-filled pen is only suitable for injecting just under the skin. Speak to your doctor if you need to inject your insulin by another method. Do not use Humulin I KwikPen: If you think hypoglycaemia (low blood sugar) is starting. Further in this leaflet it tells you how to deal with mild hypoglycaemia (see A in Section 4). If you are allergic to human insulin or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Talk to your doctor, pharmacist, or nurse before using Humulin I KwikPen •

•

If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low. Warning signs are listed later in this leaflet. You must think carefully about when to have your meals, how often to exercise and how much to do. You must also keep a close watch on your blood sugar levels by testing your blood glucose often. A few people who have had hypoglycaemia (low blood sugar) after switching from animal insulin to human insulin have reported that the early warning symptoms were less obvious or

•

• • •

different. If you often have hypoglycaemia or have difficulty recognising the symptoms, please discuss this with your doctor. If you answer YES to any of the following questions, tell your diabetes specialist nurse, doctor or pharmacist. Have you recently become ill? Do you have trouble with your kidneys or liver? Are you exercising more than usual? The amount of insulin you need may also change if you drink alcohol. You should also tell your diabetes specialist nurse, doctor or pharmacist if you are planning to go abroad. The time difference between countries may mean that you have to have your injections and meals at different times to when you are at home. Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible, if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).

Skin changes at the injection site: The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work well if you inject into a lumpy area (See How to use Humulin I KwikPen). Contact your doctor if you are currently injecting into a lumpy area before you start injecting into a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose. Other medicines and Humulin I KwikPen Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your insulin needs may change if you are taking any of the following: • steroids, • thyroid hormone replacement therapy, • oral hypoglycaemics (antidiabetic medication), • acetylsalicylic acid (aspirin), • growth hormone, • octreotide, lanreotide, • beta2 stimulants (for example ritodrine, salbutamol or terbutaline), • beta-blockers, • thiazides or some antidepressants (monoamine oxidase inhibitors), • danazol, • some angiotensin converting (ACE) inhibitors (for example captopril, enalapril) or angiotensin II receptor blockers Pregnancy, breast-feeding and fertility The amount of insulin you need usually falls during the first three months of pregnancy and increases for the remaining six months. If you are breast-feeding, you may need to alter your insulin intake or diet. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Driving and using machines Your ability to concentrate and react may be reduced if you have hypoglycaemia (low blood sugar). Please remember this in all situations where you might put yourself and others at risk (e.g. driving a car or operating machinery). You should contact your diabetes specialist nurse or doctor about the advisability of driving if you have: • frequent episodes of hypoglycaemia • reduced or absent warning signs of hypoglycaemia.

Humulin I contains Sodium This medicine contains less than 1 mmol sodium (23 mg) per dose unit, that is to say essentially 'sodium-free'. 3.

How to take it

Humulin I KwikPen

Always check the pack and the label of the pre-filled pen for the name and type of the insulin when you get it from your pharmacy. Make sure you get the Humulin I KwikPen that your doctor has told you to use. Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. To prevent the possible transmission of disease, each pen must be used by you only, even if the needle is changed. Dosage • You should normally inject Humulin I as your basal insulin. Your doctor has told you which insulin to use, how much, when and how often to inject. These instructions are only for you. Follow them exactly and visit your diabetes clinic regularly. • If you change your insulin type (for example from animal to human), you may have to take more or less than before. This might just be for the first injection or it may be a gradual change over several weeks or months. • Humulin I in pre-filled pen is only suitable for injecting just under the skin. Speak to your doctor if you need to inject your insulin by another method. Preparing Humulin I KwikPen • The KwikPen should be rotated in the palms of the hands 10 times and inverted 10 times immediately before use to resuspend insulin until it appears uniformly cloudy or milky. If not, repeat the above procedure until contents are mixed. Cartridges in the pen contain a small glass bead to assist mixing. Do not shake vigorously as this may cause frothing which may interfere with the correct measurement of the dose. The cartridges in the pen should be examined frequently and should not be used if clumps of material are present or if solid white particles stick to the bottom or sides of the cartridge, giving it a frosted appearance. Check each time you inject yourself. Getting the KwikPen ready to use (Please see user manual) • First wash your hands. • Read the instructions on how to use your pre-filled insulin pen. Please follow the instructions carefully. Here are some reminders. Use a clean needle. (Needles are not included). Prime your KwikPen before each use. This checks that insulin comes out and clears the air bubbles from your KwikPen. There may still be some small air bubbles left in the KwikPen – these are harmless, but if the air bubble is too big, it may make the dose of your injection less accurate. Injecting Humulin I • Before you make an injection, clean your skin as you have been instructed. Inject under the skin, as you were taught. Do not inject directly into a vein. After your injection, leave the needle in the skin for 5 seconds to make sure you have taken the whole dose. Do not rub the area you have just injected. Make sure you inject at least half an inch (1 cm) from where you last injected and that you 'rotate' the places you inject, as you have been taught. After injecting • As soon as you have done the injection, unscrew the needle from the KwikPen using the outer needle cap. This will keep the insulin sterile and prevent leaking. It will also stop air going back into the KwikPen and the needle clogging up. Do not share your needles or your KwikPen. Replace the cap on the KwikPen.

Further injections • Every time you use a KwikPen you must use a new needle. Before every injection, clear any air bubbles. You can see how much insulin is left by holding the KwikPen with the needle pointing down. The scale on the cartridge shows about how many units you have left. • Do not mix any other insulin in your disposable pen. Once the KwikPen is empty, do not use it again. Please get rid of it carefully – your diabetes specialist nurse or pharmacist will tell you how to do this. If you use more Humulin I than you should If you use more Humulin I than you should, your blood sugar may become low. Check your blood sugar (see A in Section 4). If you forget to use Humulin I KwikPen If you use less Humulin I than you should, your blood sugar levels may increase. Check your blood sugar. Do not inject a double dose to make up for a forgotten dose. If you stop using Humulin I KwikPen If you use less Humulin I than you should, your blood sugar levels may become too high. Do not change your insulin unless your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Human insulin may cause hypoglycaemia (low blood sugar). See more information on hypoglycaemia below in the subsection "Common problems of diabetes".

Possible side effects

Systemic allergy is very rare (affects less than 1 person in 10,000). The symptoms are as follows: • fall in blood pressure • rash over the whole body • difficulty in breathing • wheezing • fast heart beat • sweating If you think you are having this sort of insulin allergy with Humulin I, tell your doctor at once. Local allergy is common (affects less than 1 person in 10). Some people get redness, swelling or itching around the area of the insulin injection. This usually clears up in anything from a few days to a few weeks. If this happens to you, tell your doctor. Skin changes at the injection site: If you inject insulin too often at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect up to 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes. Oedema (e.g. swelling in arms, ankles; fluid retention) has been reported, particularly at the start of insulin therapy or during a change in therapy to improve control of your blood glucose.

Common problems of diabetes A. Hypoglycaemia Hypoglycaemia (low blood sugar) means there is not enough sugar in the blood. This can be caused if you: • take too much Humulin I or other insulin; • miss or delay meals or change your diet; • exercise or work too hard just before or after a meal; • have an infection or illness (especially diarrhoea or vomiting); • have a change in your need for insulin; or • have trouble with your kidneys or liver which gets worse. Alcohol and some medicines can affect your blood sugar levels. The first symptoms of low blood sugar usually come on quickly and include the following: • tiredness • rapid heartbeat • nervousness or shakiness • feeling sick • headache • cold sweat Until you become confident in recognising your warning symptoms, avoid situations such as driving a car, in which you or others would be put at risk by hypoglycaemia. Do not use Humulin I if you think hypoglycaemia (low blood sugar) is starting. If your blood sugar is low, eat glucose tablets, sugar or drink a sugary drink. Then eat fruit, biscuits, or a sandwich, as your doctor has advised you and have some rest. This will often get you over mild hypoglycaemia or a minor insulin overdose. If you get worse and your breathing is shallow and your skin gets pale, tell your doctor at once. A glucagon injection can treat quite severe hypoglycaemia. Eat glucose or sugar after the glucagon injection. If you do not respond to glucagon, you will have to go to hospital. Ask your doctor to tell you about glucagon. B. Hyperglycaemia and diabetic ketoacidosis Hyperglycaemia (too much sugar in the blood) means that your body does not have enough insulin. Hyperglycaemia can be brought about by: • not taking your Humulin I or other insulin; • taking less insulin than your doctor tells you to; • eating a lot more than your diet allows; or • fever, infection or emotional stress. Hyperglycaemia can lead to diabetic ketoacidosis. The first symptoms come on slowly over many hours or days. The symptoms include the following: • feeling sleepy • no appetite • flushed face • fruity smell on the breath • thirst • feeling or being sick Severe symptoms are heavy breathing and a rapid pulse. Get medical help immediately. If hypoglycaemia (low blood sugar) or hyperglycaemia (high blood sugar) are not treated they can be very serious and cause headaches, nausea, vomiting, dehydration, unconsciousness, coma or even death. Three simple steps to avoid hypoglycaemia or hyperglycaemia are:

  • Always keep spare syringes and a spare vial of Humulin I.
  • Always carry something to show you are diabetic.
  • Always carry sugar with you.

C. Illness If you are ill, especially if you feel sick or are sick, the amount of insulin you need may change. Even when you are not eating normally, you still need insulin. Test your urine or blood, follow your 'sick rules', and tell your diabetes specialist nurse or doctor. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.

How to store it

Humulin I KwikPen

Keep this medicine out of the sight and reach of children. Before the first use store your Humulin I KwikPen in a refrigerator (2°C – 8°C). Do not freeze. Keep your 'in use' Humulin I KwikPen at room temperature (below 30°C) for up to 28 days. Do not keep your 'in use' pen in the fridge. Do not put it near heat or in the sun. Do not use this medicine after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of that month. Do not use this medicine if you notice that clumps of material are present or solid white particles stick to the bottom or sides of the cartridge, giving it a frosted appearance. Check this each time you inject yourself. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6.

Contents of the pack and other information

What Humulin I KwikPen contains

  • The active substance is human insulin. Human insulin is made in the laboratory by a 'recombinant DNA technology' process. It has the same structure as the natural hormone made by the pancreas. It is therefore different from animal insulins. The human insulin in Humulin I is available in a suspension together with protamine sulfate. –

The other ingredients are protamine sulfate, metacresol, phenol, glycerol, dibasic sodium phosphate 7H2O, zinc oxide and water for injection. Sodium hydroxide or hydrochloric acid may have been used during manufacture to adjust the acidity.

What Humulin I KwikPen looks like and contents of the pack Humulin I (Isophane) KwikPen 100 IU/ml suspension for injection is a white, sterile suspension and contains 100 units of insulin in each millilitre (100 IU/ml). Each Humulin I KwikPen contains 300 units (3 millilitres). The Humulin I KwikPen comes in a pack of 5. The Humulin I in your KwikPen is the same as the Humulin I, which comes in separate Humulin I cartridges. The KwikPen simply has a built in cartridge. When the KwikPen is empty you cannot use it again.

Marketing Authorisation Holder and Manufacturer Humulin I KwikPen is made by: Lilly France S.A.S., Rue du Colonel Lilly, 67640 Fegersheim, France.

The marketing authorisation is held by: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.

This leaflet was last revised in September 2024. For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: United Kingdom Eli Lilly and Company Limited, Tel: + 44-(0) 1256 315000

Frequently asked questions about HUMULIN I KwikPen (Isophane) 100IU/ml suspension for injection

How do I take HUMULIN I KwikPen (Isophane) 100IU/ml suspension for injection?

HUMULIN I KwikPen (Isophane) 100IU/ml suspension for injection comes as oral solution containing 100iu/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in HUMULIN I KwikPen (Isophane) 100IU/ml suspension for injection?

The active substance in HUMULIN I KwikPen (Isophane) 100IU/ml suspension for injection is human insulin.

Are there equivalent medicines to HUMULIN I KwikPen (Isophane) 100IU/ml suspension for injection?

Medicines with the same active substance, strength and form include: HUMULIN I (Isophane) 100IU/ml suspension for injection in cartridge, HUMULIN I (Isophane) 100IU/ml suspension for injection in vial, HUMULIN M3 (Mixture 3) 100IU/ml suspension for injection in cartridge. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for HUMULIN I KwikPen (Isophane) 100IU/ml suspension for injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get HUMULIN I KwikPen (Isophane) 100IU/ml suspension for injection without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Human insulin (11 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

For the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis.

4.2. Posology and method of administration

Posology

The dosage should be determined by the physician, according to the requirement of the patient.

Paediatric population

No data are available.

Method of administration

Humulin I in pre-filled pen is only suitable for subcutaneous injections. This formulation should not be administered intravenously.

Subcutaneous administration should be in the upper arms, thighs, buttocks or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a month in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8).

Care should be taken when injecting any Humulin insulin preparations to ensure that a blood vessel has not been entered. After any insulin injection, the injection site should not be massaged. Patients must be educated to use proper injection techniques.

Each pack contains a patient information leaflet with instructions on how to inject insulin.

4.3. Contraindications

Hypoglycaemia.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1, unless used as part of a desensitisation programme.

Under no circumstances should any Humulin formulation other than Humulin S (Soluble) be given intravenously.

4.4. Special warnings and precautions for use

Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (soluble, isophane, mixture), species (animal, human, human insulin analogue), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage.

Some patients taking human insulin may require a change in dosage from that used with animal-source insulins. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months.

A few patients who experienced hypoglycaemic reactions after transfer to human insulin have reported that the early warning symptoms were less pronounced or different from those experienced with their previous animal insulin. Patients whose blood glucose is greatly improved, e.g. by intensified insulin therapy, may lose some or all of the warning symptoms of hypoglycaemia and should be advised accordingly. Other conditions which may make the early warning symptoms of hypoglycaemia different or less pronounced include long duration of diabetes, diabetic nerve disease, or medications such as beta blockers. Uncorrected hypoglycaemic and hyperglycaemic reactions can cause loss of consciousness, coma or death.

The use of dosages which are inadequate or discontinuation of treatment, especially in insulin- dependent diabetics, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal.

Treatment with human insulin may cause formation of antibodies, but titres of antibodies are lower than those to purified animal insulin.

Insulin requirements may change significantly in diseases of the adrenal, pituitary or thyroid glands and in the presence of renal or hepatic impairment.

Insulin requirements may be increased during illness or emotional disturbances.

Adjustment of insulin dosage may also be necessary if patients change their level of physical activity or change their usual diet.

Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.

Combination of human insulin with pioglitazone

Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind, if treatment with the combination of pioglitazone and human insulin is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued, if any deterioration in cardiac symptoms occurs.

Instructions for use and handling

To prevent the possible transmission of disease, each pen must be used by one patient only, even if the needle is changed.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Excipients

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially “sodium-free”.

4.5. Interaction with other medicinal products and other forms of interaction

A number of medicinal products are known to interact with glucose metabolism and therefore the physician should be consulted when using other medications in addition to human insulin (see section 4.4). The physician must therefore take possible interactions into account and should always ask his patients about any medicinal products they take.

Insulin requirements may be increased by substances with hyperglycaemic activity, such as glucocorticoids, thyroid hormones, growth hormone, danazol, beta2- sympatomimetics (such as ritodrine, salbutamol, terbutaline), thiazides.

Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics (OHA), salicylates (for example, acetylsalicylic acid), certain antidepressants (monoamine oxidase inhibitors), certain angiotensin converting enzyme (ACE) inhibitors (captopril, enalapril), angiotensin II receptor blockers, non-selective beta-blocking agents and alcohol.

Somatostatin analogues (octreotide, lanreotide) may both decrease or increase insulin dose requirements.

4.6. Fertility, pregnancy and lactation

It is essential to maintain good control of the insulin treated (insulin-dependent or gestational diabetes) patient throughout pregnancy. Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. Patients with diabetes should be advised to inform their doctors if they are pregnant or are contemplating pregnancy.

Careful monitoring of glucose control, as well as general health, is essential in pregnant patients with diabetes.

Patients with diabetes who are lactating may require adjustments in insulin dose and/or diet.

4.7. Effects on ability to drive and use machines

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).

Patients should be advised to take precautions to avoid hypoglycaemia whilst driving, this is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.

4.8. Undesirable effects

Hypoglycaemia is the most frequent undesirable effect of insulin therapy that a patient with diabetes may suffer. Severe hypoglycaemia may lead to loss of consciousness, and in extreme cases, death. No specific frequency for hypoglycaemia is presented, since hypoglycaemia is a result of both the insulin dose and other factors e.g. a patient's level of diet and exercise.

Local allergy in patients is common (≥ 1/100 to < 1/10). Redness, swelling, and itching can occur at the site of insulin injection. This condition usually resolves in a few days to a few weeks. In some instances, local reactions may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique.

Systemic allergy, which is very rare (< 1/10,000) but potentially more serious, is a generalised allergy to insulin. It may cause rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating. Severe cases of generalised allergy may be life-threatening. In the rare event of a severe allergy to Humulin, treatment is required immediately. A change of insulin or desensitisation may be required.

Lipodystrophy at the injection site is uncommon (≥ 1/1,000 to < 1/100).

Skin and subcutaneous tissue disorders: Frequency “unknown”: Cutaneous amyloidosis

Skin and subcutaneous tissue disorders:

Lipodystrophy and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (See section 4.4).

Cases of oedema have been reported with insulin therapy, particularly if previous poor metabolic control is improved by intensified insulin therapy.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via United Kingdom: Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Insulin has no specific overdose definitions, because serum glucose concentrations are a result of complex interactions between insulin levels, glucose availability and other metabolic processes. Hypoglycaemia may occur as a result of an excess of insulin relative to food intake and energy expenditure.

Hypoglycaemia may be associated with listlessness, confusion, palpitations, headache, sweating and vomiting.

Mild hypoglycaemic episodes will respond to oral administration of glucose or sugar products.

Correction of moderately severe hypoglycaemia can be accomplished by intramuscular or subcutaneous administration of glucagon, followed by oral carbohydrate when the patient recovers sufficiently. Patients who fail to respond to glucagon must be given glucose solution intravenously.

If the patient is comatose, glucagon should be administered intramuscularly or subcutaneously. However, glucose solution must be given intravenously, if glucagon is not available or if the patient fails to respond to glucagon. The patient should be given a meal as soon as consciousness is recovered.

Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may occur after apparent clinical recovery.

💬 Ask about this leaflet

Ask anything about HUMULIN I KwikPen (Isophane) 100IU/ml suspension for injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →